Engflag
Advertisements

Favoir 28

Quick links to important sections

Favoir 28

There is no image.

Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Favoir 28

Favoir 28 is defined as a combined hormonal contraceptive (CHC), a prescription-only medication formulated as an oral tablet for the purpose of preventing pregnancy. This medication belongs to the high-level pharmacological class of synthetic sex hormone analogues and is composed of two active ingredients working in synergy.

Property Description
Active ingredient Desogestrel and Ethinylestradiol
Form Oral Tablet
Pharmacological class Combined Hormonal Contraceptive (CHC)
Common use Contraception (Pregnancy Prevention)
Origin Synthetic Hormonal Preparation

Favoir 28: Defining the Combined Hormonal Contraceptive

Favoir 28's identity lies in its use of an estrogen and a progestin to regulate the reproductive cycle. Combined oral contraceptives are a clinically recognized and highly effective method for preventing pregnancy when used correctly. This type of medicine is a recognized way to achieve birth control. Favoir 28 is specifically a 28-day regimen pill in a compact blister format, which is a common way this type of hormonal birth control is packaged for daily patient compliance.

Composition and Origin: Desogestrel and Ethinylestradiol

The active composition of Favoir 28 features two key synthetic substances: Ethinylestradiol and Desogestrel. Desogestrel is notably classified as a third-generation progestin, a distinction based on its specific molecular structure and metabolic profile compared to earlier progestins. The medication contains a progestin used for its primary contraceptive action. Both components are synthetic hormonal preparations designed for oral administration, and this specific combination is also found in other popular formulations globally, such as Marvelon and Mercilon.

General Purpose of Favoir 28

The general therapeutic purpose of Favoir 28 is contraception. This function is achieved by systematically regulating the hormonal environment, resulting in the primary physiological action of suppressing the release of an egg from the ovary (ovulation). A typical neutral use scenario for Favoir 28 involves women who require effective, daily hormonal regulation to prevent an unplanned pregnancy. As a form of hormonal birth control, the medication ensures that the body's reproductive state is generally inhospitable to conception, offering its utility as a systemic preventative measure for women of reproductive age.

Regulatory References

  1. MedlinePlus Drug Information: Desogestrel and Ethinyl Estradiol
Advertisements

What side effects are possible with Favoir 28?

Possible Side Effects and Safety Information

Favoir 28, a combined hormonal contraceptive, is associated with a risk of serious health conditions, particularly cardiovascular and thrombotic events. Regulatory bodies require a Boxed Warning for this class of medicine, specifically highlighting that cigarette smoking increases the risk of serious cardiovascular events, including blood clots, heart attack, and stroke, especially in women over 35 years of age. Use is contraindicated in women over 35 who smoke.

Serious and Clinically Significant Risks

Although the absolute risk is low, serious events documented in official labeling include:

  • Thromboembolic Disorders: Formation of blood clots in the veins (venous thromboembolism, such as deep vein thrombosis and pulmonary embolism) or arteries (arterial thromboembolism, such as myocardial infarction and stroke). The risk is generally highest during the first year of use.
  • Liver Disease: Rarely, the use of oral contraceptives has been associated with benign liver tumors, which may rupture and cause life-threatening internal bleeding. There is also a potential increased risk of liver cancer.
  • Other Conditions: Hypertension, gallbladder disease, and adverse effects on lipid and carbohydrate metabolism, requiring monitoring in women with pre-existing conditions like diabetes or well-controlled high blood pressure.

Common Adverse Reactions

The most commonly reported side effects, typically less severe, include:

  • Headache, including migraine.
  • Nausea and vomiting.
  • Breast pain or tenderness.
  • Irregular uterine bleeding or spotting, particularly during the initial cycles of use.
  • Abdominal pain and malaise.

Safety Restrictions and Monitoring

Favoir 28 is contraindicated in women with a history of or high risk for arterial or venous blood clots, certain cancers (like breast cancer), severe liver disease, or undiagnosed abnormal genital bleeding. The medication must be discontinued if a patient develops jaundice, experiences a significant, sustained rise in blood pressure, or requires prolonged immobilization (e.g., due to major surgery), as these conditions increase safety risk.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Documented Acute Manifestations

Acute ingestion of an excessive dose of this combined hormonal contraceptive is officially associated with specific clinical signs. Documented manifestations include nausea and vomiting. Other noted presentations may involve vaginal bleeding, which is expected as withdrawal bleeding, as well as symptoms such as drowsiness, headache, and breast tenderness. These effects primarily involve the gastrointestinal, reproductive, and nervous systems. In young female patients, the overdose may specifically manifest with slight vaginal bleeding.

Severity and Mandated Emergency Response

Official regulatory documents classify acute overdose with this product as having low acute toxicity and state that it is not likely to be life-threatening. Regulatory reports indicate an absence of serious undesirable effects following the acute ingestion of a large dose.

Despite the low acute toxicity classification, individuals are mandated to seek immediate medical attention and contact a Poison Control Center right away if an overdose is suspected. This action ensures proper assessment and monitoring of vital signs. Management is restricted to symptomatic and supportive measures, as no specific antidote is known for this overdose. Medical assessment may include laboratory evaluation.

Advertisements

Therapeutic Uses of Favoir 28

Quick Facts

  • Primary Use: Supports the prevention of pregnancy.
  • Mechanism: Intended to help regulate the menstrual cycle.
  • Context: Used by individuals of reproductive potential as a prescribed agent.

Favoir 28 is a prescription medication utilized by females of reproductive potential to support the prevention of pregnancy. This agent contains active components that work to influence the hormonal cycle. Its primary therapeutic goal is to help maintain a non-fertile state.

Consistent use of Favoir 28 may help in supporting a regular cycle of withdrawal bleeding, which can assist in the overall management of reproductive health. This medication may also contribute to the management of premenstrual discomfort and is associated with potentially addressing certain acne concerns. As a combination oral contraceptive intended for pregnancy prevention, the use of this drug should always follow the guidance of a qualified healthcare provider.

This treatment is intended to be used as a part of a comprehensive reproductive health strategy. Individuals considering Favoir 28 should discuss its suitability and potential role with a clinician.

Regulatory References

  1. NIH DailyMed guidance on similar oral contraceptives
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Information

Favoir 28, a combined hormonal contraceptive (CHC) containing desogestrel and ethinylestradiol, is indicated for females of reproductive potential to prevent pregnancy. Eligibility is strictly defined by regulatory documents, primarily excluding those with elevated cardiovascular and thromboembolic risks.

Populations for whom use is Contraindicated (Must Not Use):

  • Cardiovascular and Thrombotic Conditions: Current or history of deep vein thrombosis, pulmonary embolism, stroke, or heart attack. This also includes known thrombophilic conditions and migraine with focal aura.
  • Smoking and Age: Females over 35 years of age who smoke.
  • Hormone-Sensitive Disease: Current or history of breast cancer or other estrogen-dependent neoplasia.
  • Hepatic Conditions: Severe hepatic disease, liver tumors, or undiagnosed abnormal uterine bleeding.
  • Pregnancy: Known or suspected pregnancy is an absolute contraindication.

Restricted and Age-Related Eligibility:

  • Use is permitted for adolescent females after menarche but is not indicated in elderly women.
  • The medicine is not recommended for use by women who are breastfeeding. In non-breastfeeding women, initiation is restricted until 4 weeks postpartum due to an increased risk of blood clots.
Advertisements

What should I know about interactions with other medicines?

Favoir 28 is a combined oral contraceptive whose effectiveness and safety can be impacted by concurrent use of certain medicines or herbal products. These interactions typically arise through the drug's hormonal components, ethinyl estradiol and desogestrel, which are metabolized by specific liver enzymes.

Significant and Contraindicated Combinations

  • Hepatitis C Combinations: Co-administration with the specific Hepatitis C virus (HCV) drug regimens containing ombitasvir, paritaprevir/ritonavir, with or without dasabuvir, is contraindicated. This combination carries a risk of significant elevations in liver enzymes (ALT), which are sometimes severe. Ethinyl estradiol-containing products must be discontinued before starting these HCV treatments.
  • Other Hormonal Contraceptives: Concomitant use with any other hormonal contraceptive is restricted due to the increased exposure to estrogen, which heightens the risk of thromboembolic events.

Interactions Affecting Efficacy

  • Enzyme Inducers: Certain medicines or herbal products that induce liver enzymes, particularly CYP3A4, can decrease the concentrations of Favoir 28's hormones in the body. This may reduce the contraceptive efficacy and increase the likelihood of breakthrough bleeding or unintended pregnancy. Examples of enzyme-inducing products include certain antiepileptic medicines and the herbal product St. John's wort (Hypericum perforatum), the use of which should be avoided.
  • Gastrointestinal Conditions: Conditions such as continuing severe diarrhea or vomiting may impair the absorption of the hormones, potentially weakening the medicinal effect and necessitating the use of alternative birth control during the affected cycle.
Advertisements

Mechanism of Action

Favoir 28 is a combination hormonal product containing two active components: a progestin, desogestrel, and an estrogen, ethinyl estradiol. The progestin component acts as an agonist at the progesterone receptor within target tissues, including the hypothalamus, pituitary gland, and ovary. The estrogen component primarily acts as an agonist at the estrogen receptor.

System-level physiological consequences are mediated by negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis. This interaction suppresses the pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus and, consequently, the pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This suppression prevents the follicle growth and the requisite LH surge, inhibiting the process of ovulation.

Independently, the progestin component alters the cellular structure and secretory activity of the cervical glandular epithelium, leading to an increase in cervical mucus viscosity and a change in its composition. Furthermore, the compounds induce atrophy and pseudodecidualization within the endometrial lining via direct cellular signaling, reducing its receptivity to blastocyst implantation.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Favoir 28 — Administration Guidelines

The administration of Favoir 28 follows a standardized, cyclic protocol for combined hormonal contraceptives. It is designated for oral use only.

Feature Guideline
Route of administration Oral (by mouth)
Dosing schedule One tablet taken daily, without interruption. The typical regimen involves 21 consecutive days of active, hormone-containing tablets, followed immediately by 7 consecutive days of inactive (placebo) tablets.
Timing in relation to meals May be taken with or without food.
Age-group administration Use is intended for women of reproductive potential but is not indicated prior to menarche or for postmenopausal individuals.
Special procedural conditions The tablets must be consumed in the sequential order designated on the blister pack. Each new 28-day cycle must begin immediately after the previous cycle is completed, maintaining continuous administration.

The fixed daily regimen is designed to ensure consistent hormonal regulation. Administration must occur at approximately the same time each day to maintain steady plasma concentrations. If a dose is missed, specific instructions must be followed depending on the stage of the cycle and the time elapsed. It is important to note that the hormone-free interval must not exceed seven days.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Favoir 28

Evidence for Use in Pregnancy Prevention (Contraception)

This combination hormonal preparation was studied for its primary purpose in pregnancy prevention. The core research base includes Randomized Controlled Trials (RCTs), which are controlled research settings, along with long-term Epidemiological Cohort Studies that studies explored patterns in large groups of users over defined time intervals. Research examined the effects of this medicine in women of reproductive potential, primarily focusing on cohorts of healthy individuals typically aged 18 to 45 years.

Researchers monitored several key factors, including the rate of pregnancy incidence among study participants, which was measured using metrics such as the Pearl Index. Studies also explored the measured outcome of inhibition of ovarian function across the observed cycles. Findings describe patterns observed in the studies, which included measurements of a low rate of pregnancy incidence among participants when the medicine was observed in a consistent daily schedule.

Regulatory reviews classify the evidence base for this combination as High-level, noting that the consistent structure of the core research contributes to the broader evidence landscape.

Research on Bleeding Patterns and Cycle Regulation

Clinical trials research examined a specific outcome related to changes in both scheduled and unscheduled uterine bleeding patterns as a primary study outcome. These multi-cycle studies explored how bleeding patterns were measured and charted over time. Studies report how symptoms evolved in the observed populations, detailing the characteristics and regularity of uterine bleeding patterns throughout the observation periods.

Long-Term Studies and Follow-up Duration

The primary evidence supporting the medicine's use was evaluated in core efficacy trials that typically used follow-up durations of up to 1 year (or 13 consecutive cycles). There is limited information for long-term outcomes regarding continued pregnancy prevention and the durability of the observed patterns beyond this initial one-year follow-up period.

What is Still Uncertain About Favoir 28

One major point data show patterns related to is that the reported effectiveness metrics are highly dependent on the study participant’s ability to achieve consistent use of the preparation. This factor introduces variability, which is an acknowledged characteristic of the research data. Additionally, comparative evidence is lacking in certain areas, limiting information from head-to-head clinical trials structured to demonstrate an advantage when comparing this specific formulation against all older generations of combined oral contraceptives regarding its efficacy structure.

Key Studies & References

  1. Combined Oral Contraceptive Pills FACT SHEET: Typical and Perfect Use Effectiveness Rates (WHO/Contraceptive Choice Sources)
  2. CPMP PUBLIC ASSESSMENT REPORT Combined oral contraceptives and venous thromboembolism: Focus on 3rd generation COCs (Desogestrel and Gestodene)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Favoir 28 (FAQ)

Q: How does Favoir 28 differ from other similar treatments for the same condition?

A: Favoir 28 contains Desogestrel, which is classified by regulatory bodies as a third-generation progestin. Official documents note that evidence from head-to-head clinical trials to demonstrate a comparative advantage over all older combined oral contraceptives is limited.

Q: Are there any known long-term side effects associated with Favoir 28 use?

A: The core clinical trial data for effectiveness and initial safety typically included follow-up periods of up to one year. However, regulatory documents describe serious and clinically significant risks, such as thromboembolic disorders (blood clots), that are long-term considerations associated with this class of medicine.

Q: Are there any specific foods or drinks that interact with Favoir 28?

A: Official information states the medicine may be taken with or without food. Severe gastrointestinal conditions like continuous diarrhea or vomiting may impair the absorption of the medicine. No specific common food or drink is listed as a significant interaction in the product information.

Q: Can people with kidney or liver issues use Favoir 28?

A: Severe hepatic disease and liver tumors are listed in official documents as contraindications (reasons not to use the drug). Specific guidance regarding kidney or renal impairment is generally not listed as an absolute contraindication for this specific combination medicine.

Q: What is the recommendation if a dose of Favoir 28 is missed?

A: Official product labeling provides specific guidance for a missed dose. The instructions are determined by the time elapsed since the dose was missed and the week of the 28-day cycle in which the dose was missed.

Q: Is Favoir 28 used for more than one health condition?

A: The medicine is primarily indicated for pregnancy prevention. Official prescribing information in certain jurisdictions may also reference studies examining outcomes related to cycle regulation and heavy menstrual bleeding (menorrhagia).

Q: How is Favoir 28 described in relation to its generic name?

A: Favoir 28 is described as a combined hormonal contraceptive. It contains two distinct active ingredients working together: the progestin desogestrel and the estrogen ethinylestradiol.

Q: What are the signs of a severe allergic reaction to Favoir 28?

A: Official documents describe signs of hypersensitivity, which can include a rash, swelling of the face, lips, tongue, or throat, and difficulty breathing. These symptoms are considered serious and may warrant immediate attention.

Q: Does Favoir 28 cause weight changes, based on clinical trial data?

A: According to clinical trial data for combined oral contraceptives, weight changes are reported among the adverse reactions. This includes reports of both weight gain and weight loss.

Q: Does Favoir 28 affect energy levels or cause fatigue?

A: Official labeling lists fatigue (lack of energy) and general malaise among the adverse drug reactions reported by individuals using the medicine.

Q: Can Favoir 28 cause problems with sleep or insomnia?

A: Insomnia, which is difficulty sleeping, is listed in the official prescribing information as one of the reported nervous system adverse reactions.

Q: Does Favoir 28 interact with common over-the-counter pain relievers?

A: Regulatory documents identify certain strong enzyme-inducing medicines that can affect efficacy. Common over-the-counter pain relievers are generally not listed as significant interactions in the official product information.

Q: Is there an interaction described between Favoir 28 and alcohol consumption?

A: Official information does not list a specific interaction or contraindication regarding the concurrent consumption of alcohol with Favoir 28.

Q: Is Favoir 28 listed as interacting with high-caffeine products?

A: Official information does not list caffeine or high-caffeine products as a significant interaction that affects the efficacy or safety of the medicine.

Q: How quickly can a person expect Favoir 28 to start working?

A: Official guidance indicates when contraceptive protection begins, which is dependent upon the day of the menstrual cycle the first dose is administered. The specific instructions for administration should be followed to ensure contraceptive protection.

Q: Does Favoir 28 need to build up in the body to reach full effect?

A: The medicine is designed for continuous daily use to achieve and maintain consistent hormonal regulation and steady plasma concentrations.

Q: What is the expected duration of effect after taking one dose of Favoir 28?

A: The pharmacological effect of the active ingredients is described by their elimination half-life. For the active metabolite of desogestrel, the half-life is approximately 38 hours at steady state, supporting consistent effect with daily dosing.

Q: What is meant by the term 'peak concentration' when referring to Favoir 28?

A: Peak concentration (Cmax) is a pharmacological term used to describe the highest measured amount of the medicine’s active ingredient that is present in the bloodstream following administration.

Q: Why do people on social media sometimes mention 'Favoir fog'?

A: The term 'Favoir fog' is not used in official sources. However, regulatory documents list certain nervous system adverse reactions, including headache and dizziness, as possible effects of the medicine.

Q: What is the meaning of the number '28' in the drug name Favoir 28?

A: Favoir 28 is named after the regimen length, which is a 28-day cycle. This includes 21 active tablets followed by 7 inactive (placebo) tablets.

Q: Has Favoir 28 been studied for any off-label uses recently?

A: The core research is focused on contraception, but clinical trials research has also examined themes related to cycle regulation and changes in uterine bleeding patterns.

Q: Is Favoir 28 known to cause changes to vision or hearing?

A: Regulatory documentation describes the potential for serious, rare side effects such as vision changes. This may be an indication of a serious, rare thromboembolic event in the eye, such as retinal vascular thrombosis.

Q: Are there any known withdrawal effects when stopping Favoir 28?

A: The official description of the drug's effect describes that the normal function of the ovaries and the return to fertility are generally expected soon after discontinuing use. This may involve a return to previous menstrual cycle characteristics.

Advertisements

How should Favoir 28 be stored and disposed of?

How to Store and Dispose of Favoir 28?

To maintain the chemical stability of Favoir 28, official regulatory documents require strict adherence to specific storage and disposal protocols.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and do not store above 30^ C.
Container Rule Keep the medicine in its original container, which must be tightly closed and properly labeled.
Prohibitions Keep away from excessive heat, flames, sources of ignition, and avoid breathing the product dust.
Child Safety For safety, the medicine must be stored locked up, out of the sight and reach of children.

Disposal Instructions

The disposal of unused or expired Favoir 28 must be performed in compliance with applicable local or national governmental regulations for pharmaceutical waste. Due to its classification as a hazardous drug, it is critical to prevent the release of the product into the environment, including avoiding disposal in wastewater or down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Favoir 28 found in:

A-Z Index: